ACC 2021: Pirfenidone Reduces Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction
Pirfenidone is the first agent to reduce myocardial fibrosis without producing hemodynamic effects
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.